Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mycophenolate sodium + steroids is a **combination immunosuppressive regimen** used primarily in the prevention of organ rejection (notably in kidney transplantation) and in certain immune-mediated diseases (e.g., glomerulonephritis, nephritis). **Mycophenolate sodium** (in the brand form Myfortic) is a prodrug of mycophenolic acid, a selective, non-competitive inhibitor of the enzyme inosine monophosphate dehydrogenase, thereby inhibiting de novo purine synthesis in T and B lymphocytes. **Steroids** (glucocorticoids, such as prednisone or methylprednisolone) act via the glucocorticoid receptor, altering gene transcription to broadly suppress inflammation and immune activation. The combination is standard in transplant protocols and for some autoimmune conditions[3][4][1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mycophenolate sodium + steroids.